IP Cell
Ensuring the Ethics and Business Integrity of Medicines
IP Cell was set up in 2009 to safeguard the interest of public health and national companies and is tasked to examine all pharmaceuticals and biopharmaceuticals patents applications.
Through the IP Cell, any healthcare professional, company, or public member may file a complaint reporting a breach related to the examination and quality of patents in India.
Code of Practice Complaint Submission
The IP cell examines all patent applications relating to pharmaceuticals and biopharmaceuticals published from
1st January 2009 and applications published before
31st December 2008 which have not been processed.
Innovation
The Indian pharmaceutical industry has established itself in terms of scale and reach. Since the industry is knowledge-driven, research and innovation are key drivers to enable the industry to achieve value leadership and cater to the unmet needs of patient care. At IPA, we collaborate with the Government, academia and industry on policy, regulatory and funding initiatives to foster a vibrant ecosystem catalysing Innovation and R&D in India. These initiatives will enable India to move to “Discover and Make in India, for India and the world” from “Make in India”
Global Research
The Indian pharmaceutical industry has established itself as a global leader by supplying crucial drugs to more than 200 countries. In line with the vision of ‘Atmanirbhar Bharat’, the Indian pharma industry has been achieving greater heights. Contributing towards global health, the Indian pharma industry caters to more than 60 per cent of the global demand for different vaccines and is the largest provider of generic medicines. IPA is committed to further enhancing India’s position as a leader in the global pharmaceuticals sector.
